Keros Therapeutics
Edit info- Founded: 2015
- Location: Lexington, MA
- Employee range: 50 - 200
- Clinical stage: Clin2
- Therapy area: Myelodysplastic syndromes
- Drug types: ONC, HEM, MUS
- Lead product: KER-050
- Funding: $110M IPO Apr 2020; $23M B Jan 2019; $11M A 2016
- Investors: Pontifax, Arkin Bio Ventures, Partners Innovation Fund, Medison Pharma, Global Health Sciences Fund
kerostx.com linkedin.com job board
Business:
Rare Muscle Disorders
Drug notes:
Also Clin2 myelofibrosis; KER-047 Clin2 iron deficiency anemia, Clin1 iron deficiency anemia in MDS & MF; KER-012 Clin1PAH; undisclosed Clin0 musculoskeletal conditions
About:
Keros Therapeutics is discovering and developing treatments for rare hematologic and musculoskeletal disorders. A wide range of disorders are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-β). At Keros, they are using their protein engineering and drug development expertise to uncover targets within the TGF-β superfamily. By developing therapeutics that can intervene in this pathway, Keros aims to target pathways critical for the growth, repair and maintenance of blood cells and a number of tissues including bone, skeletal muscle, adipose and heart tissue.
© 2025 Work In Biotech LLC
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com